Acadia Pharmaceuticals Reports Strong Q1 Revenue Growth, Reaffirms 2026 Guidance

summarizeSummary

Acadia Pharmaceuticals announced its first quarter 2026 financial results, reporting significant revenue growth for its key products DAYBUE and NUPLAZID, while reaffirming its full-year 2026 financial guidance.

check_boxKey Events

• Strong Q1 Revenue Growth

  Total revenues increased 10% year-over-year to $268 million for the first quarter of 2026.

• Key Product Sales Performance

  DAYBUE net sales rose 20% to $101 million, with NUPLAZID net sales increasing 5% to $167 million. The launch of DAYBUE STIX is progressing well.

• Full-Year Guidance Reaffirmed

  The company reiterated its 2026 financial guidance, indicating that Q1 results align with its annual projections.

• Increased SG&A Impacts Net Income

  Net income for the quarter was $4 million, down from $19 million in Q1 2025, primarily due to higher selling, general, and administrative expenses supporting product growth.

auto_awesomeAnalysis

Acadia Pharmaceuticals reported a solid first quarter for 2026, with total revenues increasing 10% year-over-year to $268 million, driven by strong sales of DAYBUE and NUPLAZID. DAYBUE sales notably grew 20% to $101 million, supported by the successful launch of DAYBUE STIX. While net income decreased significantly to $4 million due to increased selling, general, and administrative expenses, these investments are aimed at supporting continued product growth. Crucially, the company reaffirmed its full-year 2026 financial guidance, signaling that performance is in line with management's expectations. Positive pipeline updates, including remlifanserin's Phase 2 results remaining on track and accelerated enrollment for trofinetide in Japan, further support the company's long-term outlook.